Hypothesis: Ubiquitin ligase reporter assay

Query: You are a professional biomedical researcher, having experience in early-stage drug discovery and validation in vitro. Your task is to evaluate cell culture assays that would be used to evaluate drugs to treat sarcopenia.
        Given the following assay, do a comprehensive literature review to evaluate if this assay would be useful for testing therapeutics for sarcopenia. Search relevant literature across
        biomedical, clinical, and biochemical literature about the disease or therapeutic landscape. Don't look up specific drugs, but any relevant scientific information that may inform assay development.Strategy: Ubiquitin ligase reporter assay
Reasoning: Use a luciferase reporter under control of the MuRF1 or Atrogin-1 promoter in myotubes to screen for inhibitors of UPS‐mediated proteolysis. Fast luminescence readout directly reflects E3 ligase transcription, a hallmark of muscle atrophy (LeBrasseur et al. 2019).Provide your response in the following format, like an evaluation for a scientific proposal:
        Assay Overview: Explain the assay idea, including the following key points: which aspect of the disease pathogenesis does the assay model, what measurements will be taken from the assay and how they will be taken, which cells or other biological material are used in the assay.
        Biomedical Evidence: Make a compelling argument for how the aspect of the disease represented in the assay is central to the pathogenesis of the disease. Make sure to consider both the biomedical and clinical literature.
        Previous Use: Explain how this assay has previously been used for drug discovery (if this has been done). Explain any key scientific discoveries which have been made using this assay.
        Overall Evaluation: Strengths and weaknesses of this assay for testing therapeutics for sarcopenia.

Assay Overview:
The proposed assay utilizes a luciferase reporter gene driven by either the MuRF1 or Atrogin-1 promoter in differentiated myotubes derived from skeletal muscle cells. The assay is designed to model the key pathological process of enhanced ubiquitin–proteasome system (UPS)–mediated proteolysis observed in sarcopenia. By measuring luminescence after adding candidate compounds, it offers a direct readout of E3 ubiquitin ligase transcriptional activity. The detection is achieved using standard plate‐based luminometry, where a decrease in luminescence implies that the compound can inhibit the transcription of these atrogenes (OpenTargets Search: Sarcopenia-MuRF1,Atrogin-1). This in vitro setup recapitulates aspects of muscle cell biology and the molecular events that precede protein degradation in atrophic conditions.

Biomedical Evidence:
The central role of UPS activation in muscle atrophy is well documented; both MuRF1 and Atrogin-1 are consistently upregulated in skeletal muscle during conditions such as sarcopenia, cancer cachexia, and heart failure. Transcriptional induction of these ligases is regulated through pathways including the PI3K/Akt-FoxO axis and mTOR signaling. In particular, FoxO transcription factors have been highlighted as key drivers of their expression in muscle wasting states, thereby linking catabolic stimuli (e.g., glucocorticoids, inflammatory cytokines) to enhanced protein degradation (bois2014transcriptionalregulationof pages 13-16, lee2020docosahexaenoicacida pages 3-5). The clinical relevance is underscored by correlations observed between increased expression of these ligases and reduced muscle mass in aging populations. Such evidence establishes UPS-mediated proteolysis as a pivotal mechanism in the pathogenesis of sarcopenia, validating the use of a luciferase reporter assay as a proxy to monitor these transcriptional events (gellhaus2023therapeuticconsequencesof pages 1-2, kaiser2022dualrolesof pages 1-2).

Previous Use:
Historically, luciferase reporter assays under the control of the MuRF1 or Atrogin-1 promoters have been used to noninvasively monitor muscle atrophy. For instance, transgenic models featuring MuRF1-driven luciferase have demonstrated that changes in bioluminescent output accurately correspond with muscle atrophy induced by denervation, glucocorticoid treatment, and disuse (li2014noninvasiveimagingof pages 1-2, li2014noninvasiveimagingof pages 3-5). Additionally, in vitro studies employing similar promoter-driven reporters in myotube cultures have provided insights into the transcriptional regulation of UPS activation. These applications have facilitated early-stage drug screening by allowing rapid and sensitive assessments of compound efficacy in suppressing atrogene expression (bois2014transcriptionalregulationof pages 16-21, li2014noninvasiveimagingof pages 12-13).

Overall Evaluation:
The assay’s primary strength lies in its focus on a well-characterized and disease-specific molecular event in sarcopenia—the transcriptional activation of UPS components mediated by MuRF1 and Atrogin-1. Its fast luminescence readout is both quantitative and adaptable to high-throughput screening, which is valuable for early drug discovery efforts (kalan2024evaluatingtherole pages 12-16). Using differentiated muscle cell models also adds translational value by closely mimicking the cellular environment of skeletal muscle.

However, inherent limitations must be considered. The assay measures transcriptional activity and does not directly capture downstream proteolytic events or changes in muscle fiber architecture. Sarcopenia is multifactorial; while UPS-mediated proteolysis is central, aspects such as impaired satellite cell function, oxidative stress, and mitochondrial dysfunction also contribute to the disease (fernandezlazaro2022potentialsatellitecelllinked pages 4-6, kalan2024evaluatingtherole pages 16-20). Consequently, while the luciferase reporter readout provides a robust screening tool to detect compounds that modulate the expression of key atrogenes, it should be considered as part of a broader panel of assays addressing additional pathogenic mechanisms. Complementary studies evaluating muscle fiber morphology, regeneration capacity, and contractile function would be necessary to fully validate therapeutic efficacy for sarcopenia.

In summary, the ubiquitin ligase luciferase reporter assay is a scientifically sound and efficient platform for the early-stage screening of compounds targeting UPS-mediated muscle atrophy. When integrated with additional functional assays, it holds significant promise for advancing the discovery of therapeutics to treat sarcopenia (OpenTargets Search: Sarcopenia-MuRF1,Atrogin-1, bois2014transcriptionalregulationof pages 13-16).

References:
1. (OpenTargets Search: Sarcopenia-MuRF1,Atrogin-1): Open Targets Query (Sarcopenia-MuRF1,Atrogin-1, 2 results). Ochoa, D. et al. (2023). The next-generation Open Targets Platform: reimagined, redesigned, rebuilt. Nucleic Acids Research.

2. (bois2014transcriptionalregulationof pages 13-16): PD Bois. Transcriptional regulation of murf1 in skeletal muscle atrophy. Unknown journal, Dec 2014. URL: https://doi.org/10.18452/17079, doi:10.18452/17079. This article has 0 citations.

3. (bois2014transcriptionalregulationof pages 16-21): PD Bois. Transcriptional regulation of murf1 in skeletal muscle atrophy. Unknown journal, Dec 2014. URL: https://doi.org/10.18452/17079, doi:10.18452/17079. This article has 0 citations.

4. (fernandezlazaro2022potentialsatellitecelllinked pages 4-6): Diego Fernández-Lázaro, Evelina Garrosa, Jesús Seco-Calvo, and Manuel Garrosa. Potential satellite cell-linked biomarkers in aging skeletal muscle tissue: proteomics and proteogenomics to monitor sarcopenia. Proteomes, 10:29, Aug 2022. URL: https://doi.org/10.3390/proteomes10030029, doi:10.3390/proteomes10030029. This article has 39 citations and is from a peer-reviewed journal.

5. (gellhaus2023therapeuticconsequencesof pages 1-2): Benjamin Gellhaus, Kai O. Böker, Arndt F. Schilling, and Dominik Saul. Therapeutic consequences of targeting the igf-1/pi3k/akt/foxo3 axis in sarcopenia: a narrative review. Cells, 12:2787, Dec 2023. URL: https://doi.org/10.3390/cells12242787, doi:10.3390/cells12242787. This article has 18 citations and is from a peer-reviewed journal.

6. (kaiser2022dualrolesof pages 1-2): Marco S. Kaiser, Giulia Milan, Shuo Lin, Filippo Oliveri, Kathrin Chojnowska, Lionel A. Tintignac, Nitish Mittal, Christian E. Zimmerli, David J. Glass, Mihaela Zavolan, Daniel J. Ham, and Markus A. Rüegg. Dual roles of mtorc1-dependent activation of the ubiquitin-proteasome system in muscle proteostasis. BioRxiv, Nov 2022. URL: https://doi.org/10.1101/2021.11.16.468773, doi:10.1101/2021.11.16.468773. This article has 27 citations.

7. (kalan2024evaluatingtherole pages 12-16): JJ Kalan. Evaluating the role of micrornas in ageing skeletal muscle. Unknown journal, 2024.

8. (kalan2024evaluatingtherole pages 16-20): JJ Kalan. Evaluating the role of micrornas in ageing skeletal muscle. Unknown journal, 2024.

9. (lee2020docosahexaenoicacida pages 3-5): Jung Hoon Lee, Jun Hyoung Jeon, and Min Jae Lee. Docosahexaenoic acid, a potential treatment for sarcopenia, modulates the ubiquitin–proteasome and the autophagy–lysosome systems. Nutrients, 12:2597, Aug 2020. URL: https://doi.org/10.3390/nu12092597, doi:10.3390/nu12092597. This article has 46 citations and is from a peer-reviewed journal.

10. (li2014noninvasiveimagingof pages 1-2): Wei Li, Mark D. Claypool, Annabelle M. Friera, John McLaughlin, Kristen A. Baltgalvis, Ira J. Smith, Taisei Kinoshita, Kathy White, Wayne Lang, Guillermo Godinez, Donald G. Payan, and Todd M. Kinsella. Noninvasive imaging of in vivo murf1 expression during muscle atrophy. PLoS ONE, 9:e94032, Apr 2014. URL: https://doi.org/10.1371/journal.pone.0094032, doi:10.1371/journal.pone.0094032. This article has 5 citations and is from a peer-reviewed journal.

11. (li2014noninvasiveimagingof pages 12-13): Wei Li, Mark D. Claypool, Annabelle M. Friera, John McLaughlin, Kristen A. Baltgalvis, Ira J. Smith, Taisei Kinoshita, Kathy White, Wayne Lang, Guillermo Godinez, Donald G. Payan, and Todd M. Kinsella. Noninvasive imaging of in vivo murf1 expression during muscle atrophy. PLoS ONE, 9:e94032, Apr 2014. URL: https://doi.org/10.1371/journal.pone.0094032, doi:10.1371/journal.pone.0094032. This article has 5 citations and is from a peer-reviewed journal.

12. (li2014noninvasiveimagingof pages 3-5): Wei Li, Mark D. Claypool, Annabelle M. Friera, John McLaughlin, Kristen A. Baltgalvis, Ira J. Smith, Taisei Kinoshita, Kathy White, Wayne Lang, Guillermo Godinez, Donald G. Payan, and Todd M. Kinsella. Noninvasive imaging of in vivo murf1 expression during muscle atrophy. PLoS ONE, 9:e94032, Apr 2014. URL: https://doi.org/10.1371/journal.pone.0094032, doi:10.1371/journal.pone.0094032. This article has 5 citations and is from a peer-reviewed journal.
